Liver Cancer
S. Karger AG · Switzerland · Est. 1985
Aims & Scope✦ Inferred from recent articles
This journal focuses on hepatocellular carcinoma (HCC), investigating various treatment modalities including systemic therapies (atezolizumab, bevacizumab, lenvatinib, durvalumab, tremelimumab, nivolumab, ipilimumab, botensilimab, balstilimab), intra-arterial therapies (TACE, HAIC), stereotactic body radiation therapy (SBRT), and hepatic resection. It also covers liver transplantation (LT) eligibility and outcomes, as well as diagnostic imaging and risk factor trajectories for HCC development.
AI-summarised from recent articles · verify on publisher page →
General Information
Submission Info
Ethics & Quality
Think.Check.Submit Compliance
Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.
Publication & Citation Trend
Source: OpenAlex · Note: citations accumulate over time so older years appear higher
SJR Quartile by Discipline
Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.
Subject Classification
Web of Science Categories
Scopus Categories
Research Topics (OpenAlex)
You May Also Like
See all →Data updated: 2026-05-22 · Sources: SJR, DOAJ, OpenAlex, WoS, Crossref